Cat. No. 2676
Chemical Name: [6-Hydroxy-2-(4-hydroxyphenyl)benzo
Biological ActivitySelective estrogen receptor modulator (SERM) that displays selectivity for ERα over ERβ (Ki values are 0.09 and 11.31 nM respectively) and no cross-reactivity with mineralocorticoid, glucocorticoid, androgen and progesterone receptors. Acts as an agonist in the bone and antagonist in reproductive tissue. Suppresses estrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Ning et al (2007) Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). Br.J.Pharmacol. 150 19. PMID: 17115070.
Yang et al (2005) Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor α and their bioactivities in vivo. Bioorg.Med.Chem.Lett. 15 1505. PMID: 15713417.
If you know of a relevant reference for Y 134 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Y 134 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Y 134, supplier, Selective, estrogen, receptor, modulators, SERM, selective, Erα, Eralpha, ERR, Estrogen, Receptors, Y134, Tocris Bioscience, Estrogen and Related Receptor Modulator products
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogC-DIM 12
Nurr1 activator; inhibits NF-κB-dependent gene expression(S)-Equol
Potent estrogen receptor β (ERβ) agonistAilanthone
Potent inhibitor of androgen receptor (AR)(±)-ML 209
RORγt inverse agonist; suppresses Th17 cell differentiationAGN 193109
High affinity pan-RAR antagonistSR 9243
Selective LXR inverse agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.